Stock Taper
| DATE | TYPE | RATIO |
|---|---|---|
| 2024-08-09 | Reverse | 1:12 |
| 2023-11-30 | Reverse | 1:20 |
Cingulate Inc. is a clinical-stage biopharmaceutical company developing treatments for ADHD and anxiety, with lead candidates CTx-1301 (phase 3) and CTx-1302, based in Kansas City, Kansas.

CTx-1301 is a late-stage, once-daily ADHD treatment by Cingulate, utilizing their proprietary PTR™ platform, with an FDA-submitted NDA, offering fast onset and all-day efficacy.
Overall rating: C+
| PEER | PRICE | |
|---|---|---|
BCTX | $3.73 | COMPARE |
ALLR | $1.41 | COMPARE |
LEXX | $10.35 | COMPARE |
SYBX | $1.22 | COMPARE |
NCNA | $1.76 | COMPARE |